Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA.
Anesth Analg. 2010 Nov;111(5):1101-9. doi: 10.1213/ANE.0b013e3181dd9516. Epub 2010 May 10.
Heart-type fatty acid binding protein (hFABP) functions as a myocardial fatty acid transporter and is released into the circulation early after myocardial injury. We hypothesized that hFABP is superior to conventional cardiac biomarkers for predicting early perioperative myocardial injury after coronary artery bypass graft (CABG) surgery.
A prospective cohort study of 1298 patients undergoing primary CABG with cardiopulmonary bypass (CPB) was performed at 2 institutions. Four plasma myocardial injury biomarkers (hFABP; cardiac troponin I [cTnI]; creatine kinase, MB [CK-MB] fraction; and myoglobin) were measured at 7 perioperative time points. The association among perioperative cardiac biomarkers and ventricular dysfunction, hospital length of stay (HLOS), and up to 5-year postoperative mortality (median 3.3 years) was assessed using Cox proportional hazard models. We defined in-hospital ventricular dysfunction as a new requirement for 2 or more inotropes, or new placement of an intraaortic balloon pump, or ventricular assist device either during the intraoperative period after the patient separated from CPB or postoperatively in the intensive care unit.
The positive and negative predictive values of mortality for hFABP are 13% (95% confidence interval [CI], 9%-19%) and 95% (95% CI, 94%-96%), respectively, which is higher than for cTnI and CK-MB. After adjusting for clinical predictors, both postoperative day (POD) 1 and peak hFABP levels were independent predictors of ventricular dysfunction (P < 0.0001), HLOS (P < 0.05), and 5-year mortality (P < 0.0001) after CABG surgery. Furthermore, POD1 and peak hFABP levels were significantly superior to other evaluated biomarkers for predicting mortality. In a repeated-measures analysis, hFABP outperformed all other models of fit for HLOS. Patients with POD2 hFABP levels higher than post-CPB hFABP levels had an increased mortality compared with those patients whose POD2 hFABP levels decreased from their post-CPB level (hazard ratio, 10.9; 95% CI, 5.0-23.7; P = 7.2 × 10(-10)). Mortality in the 120 patients (10%) with a later hFABP peak was 18.3%, compared with 4.7% in those who did not peak later. Alternatively, for cTnI or CK-MB, no difference in mortality was detected.
Compared with traditional markers of myocardial injury after CABG surgery, hFABP peaks earlier and is a superior independent predictor of postoperative mortality and ventricular dysfunction.
心脏型脂肪酸结合蛋白(hFABP)作为心肌脂肪酸转运蛋白,在心梗后早期释放入血循环。我们假设 hFABP 比传统心脏生物标志物更能预测冠脉搭桥术(CABG)后早期围术期心肌损伤。
在 2 家机构对 1298 例行体外循环(CPB)下 CABG 的患者进行前瞻性队列研究。在 7 个围术期时间点检测 4 种血浆心肌损伤生物标志物(hFABP;肌钙蛋白 I [cTnI];肌酸激酶同工酶 MB [CK-MB]片段;和肌红蛋白)。使用 Cox 比例风险模型评估围术期心脏生物标志物与心室功能障碍、住院时间(HLOS)和术后 5 年死亡率(中位数 3.3 年)之间的关系。我们将术中 CPB 脱机后 ICU 期间需要 2 种或更多正性肌力药或新置入主动脉内球囊泵或心室辅助装置的新要求定义为院内室性功能障碍。
hFABP 对死亡率的阳性和阴性预测值分别为 13%(95%置信区间 [CI],9%-19%)和 95%(95% CI,94%-96%),高于 cTnI 和 CK-MB。在调整临床预测因子后,术后第 1 天(POD1)和峰值 hFABP 水平均是术后室性功能障碍(P < 0.0001)、HLOS(P < 0.05)和术后 5 年死亡率(P < 0.0001)的独立预测因子。此外,POD1 和峰值 hFABP 水平在预测死亡率方面明显优于其他评估的生物标志物。在重复测量分析中,hFABP 在 HLOS 方面优于其他所有拟合模型。与术后第 2 天 hFABP 水平下降的患者相比,术后第 2 天 hFABP 水平高于 CPB 后 hFABP 水平的患者死亡率更高(风险比,10.9;95% CI,5.0-23.7;P = 7.2×10(-10))。120 例(10%)hFABP 峰值较晚患者的死亡率为 18.3%,而无 hFABP 峰值较晚患者的死亡率为 4.7%。相反,cTnI 或 CK-MB 则未发现死亡率差异。
与 CABG 术后传统心肌损伤标志物相比,hFABP 升高更早,是术后死亡率和心室功能障碍的更优独立预测因子。